Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA’s Current Standpoint on PFAS Includes Phaseouts and Regulatory Changes

The FDA is currently monitoring a phase-out of short chain PFAS and proposing regulatory changes to improve its ability to revoke food contact authorizations for such substances.

The FDA's proposed changes to food contact notification regulations would apply to all food contact substances, not just PFAS.
The FDA's proposed changes to food contact notification regulations would apply to all food contact substances, not just PFAS.
Sarah Silbiger via Getty Images

The FDA is proposing regulatory changes and monitoring certain food contact substance phase-outs to help limit the use of per- and polyfluoroalkyl substances (PFAS) in food packaging.

PFAS is commonly used in four main food-contact areas: non-stick applications, food processing equipment parts, processing aids, and grease-proofing agents, according to Dr. Sharon Koh-Fallet, regulatory review branch chief at the FDA’s division of food contact substances. Koh-Fallet spoke at the November 2 PFAS: Impact on the Planet and Solutions for the Packaging Industry event in Madison, Wisconsin.

Dozens of attendees listened in on Koh-Fallet's presentation at the November 2 PFAS even in Madison, WI.Dozens of attendees listened in on Koh-Fallet's presentation at the November 2 PFAS even in Madison, WI.Certain PFAS are persistent in the environment, and can accumulate in plants, animals, and humans, and are associated with adverse health effects in humans and animals.

“Whether that’s immunotoxicity, or reproductive and developmental toxicity, which are some of the more common toxicity effects that we’ve seen,” Koh-Fallet explains, adding, “for some certain PFAS, there’s also been evidence of carcinogenicity as well as other systemic toxicity.”

FDA Monitoring PFAS Phaseouts

Industries have already phased out some more dangerous PFAS types. A phase-out of perfluorooctane sulfonic acid (PFOS) began in 2000, and a voluntary industry agreement was made in 2011 to discontinue the use of seven long-chain PFAS that were authorized under the Food Contact Notification (FCN) program.

In 2016, the FDA revoked FCN authorization of three of these long-chain PFAS due to safety concerns, and two more based on abandonment or discontinued use.

Regulations are tightening for short-chain PFAS as well. The FDA recently conducted a post-market review of the short-chain PFAS 6:2 fluorotelomer alcohol (6:2 FTOH) and found bio-persistence and increased risks of immunotoxicity, developmental and reproductive issues, and carcinogenicity.

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging